abiraterone,olaparib
astrazeneca,merck
['#gu,(-#gui),(-#gunagratinib),(-#guard),(-#gut)', 'propel']
final os analysis of propel: no significant benefit in itt, but more remarkable effect for hrrm. so everything comes back to the same point: should we test for hrr or not? #gu23 
Medical Oncologist - Urologic Oncology. Hospital Universitario La Paz - IdiPAZ, Madrid